{"id":"NCT03066830","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea Alone or in Combination With Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a Sulfonylurea Alone or With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-24","primaryCompletion":"2019-04-17","completion":"2019-04-30","firstPosted":"2017-02-28","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin (SAR439954)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Sulfonylurea","otherNames":[]}],"arms":[{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on Hemoglobin A1c (HbA1c) reduction at Week 26 in participant with type 2 diabetes (T2D) who have inadequate glycemic control with a Sulfonylurea alone or in combination with Metformin.\n\nSecondary Objectives:\n\n* To compare Sotagliflozin 400 mg versus placebo based on:\n* Change from baseline in fasting plasma glucose (FPG).\n* Change from baseline in systolic blood pressure (SBP) for participants with baseline SBP â‰¥130 millimeter of mercury (mm Hg).\n* Change from baseline in SBP for all participants.\n* Change from baseline in body weight.\n* Percentage of participants with HbA1c \\<6.5% and \\<7.0%.\n* To evaluate the safety of Sotagliflozin 400 mg versus placebo throughout the 79-week trial.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":0.06,"sd":0.082},{"arm":"Sotagliflozin 400 mg","deltaMin":-0.7,"sd":0.068}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":76,"countries":["United States","Bulgaria","Estonia","Hungary","Poland","Romania","Slovakia","South Korea","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":253},"commonTop":["Hyperglycaemia","Nasopharyngitis","Diarrhoea","Upper respiratory tract infection","Urinary tract infection"]}}